160 related articles for article (PubMed ID: 27695661)
1. Staufen1s role as a splicing factor and a disease modifier in Myotonic Dystrophy Type I.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Jasmin BJ; Côté J
Rare Dis; 2016; 4(1):e1225644. PubMed ID: 27695661
[TBL] [Abstract][Full Text] [Related]
2. Staufen1 Regulates Multiple Alternative Splicing Events either Positively or Negatively in DM1 Indicating Its Role as a Disease Modifier.
Bondy-Chorney E; Crawford Parks TE; Ravel-Chapuis A; Klinck R; Rocheleau L; Pelchat M; Chabot B; Jasmin BJ; Côté J
PLoS Genet; 2016 Jan; 12(1):e1005827. PubMed ID: 26824521
[TBL] [Abstract][Full Text] [Related]
3. The RNA-binding protein Staufen1 is increased in DM1 skeletal muscle and promotes alternative pre-mRNA splicing.
Ravel-Chapuis A; Bélanger G; Yadava RS; Mahadevan MS; DesGroseillers L; Côté J; Jasmin BJ
J Cell Biol; 2012 Mar; 196(6):699-712. PubMed ID: 22431750
[TBL] [Abstract][Full Text] [Related]
4.
Bosè F; Renna LV; Fossati B; Arpa G; Labate V; Milani V; Botta A; Micaglio E; Meola G; Cardani R
Front Neurol; 2019; 10():992. PubMed ID: 31611837
[TBL] [Abstract][Full Text] [Related]
5. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy.
Savkur RS; Philips AV; Cooper TA
Nat Genet; 2001 Sep; 29(1):40-7. PubMed ID: 11528389
[TBL] [Abstract][Full Text] [Related]
6. Staufen1 impairs stress granule formation in skeletal muscle cells from myotonic dystrophy type 1 patients.
Ravel-Chapuis A; Klein Gunnewiek A; Bélanger G; Crawford Parks TE; Côté J; Jasmin BJ
Mol Biol Cell; 2016 Jun; 27(11):1728-39. PubMed ID: 27030674
[TBL] [Abstract][Full Text] [Related]
7. Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1.
Leroy O; Wang J; Maurage CA; Parent M; Cooper T; Buée L; Sergeant N; Andreadis A; Caillet-Boudin ML
Biochim Biophys Acta; 2006 Apr; 1762(4):460-7. PubMed ID: 16487687
[TBL] [Abstract][Full Text] [Related]
8. Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.
Manta A; Stouth DW; Xhuti D; Chi L; Rebalka IA; Kalmar JM; Hawke TJ; Ljubicic V
J Physiol; 2019 Mar; 597(5):1361-1381. PubMed ID: 30628727
[TBL] [Abstract][Full Text] [Related]
9. Brugada syndrome and abnormal splicing of SCN5A in myotonic dystrophy type 1.
Wahbi K; Algalarrondo V; Bécane HM; Fressart V; Beldjord C; Azibi K; Lazarus A; Berber N; Radvanyi-Hoffman H; Stojkovic T; Béhin A; Laforêt P; Eymard B; Hatem S; Duboc D
Arch Cardiovasc Dis; 2013 Dec; 106(12):635-43. PubMed ID: 24140416
[TBL] [Abstract][Full Text] [Related]
10. Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds.
Arandel L; Polay Espinoza M; Matloka M; Bazinet A; De Dea Diniz D; Naouar N; Rau F; Jollet A; Edom-Vovard F; Mamchaoui K; Tarnopolsky M; Puymirat J; Battail C; Boland A; Deleuze JF; Mouly V; Klein AF; Furling D
Dis Model Mech; 2017 Apr; 10(4):487-497. PubMed ID: 28188264
[TBL] [Abstract][Full Text] [Related]
11. Macroscopic and microscopic diversity of missplicing in the central nervous system of patients with myotonic dystrophy type 1.
Furuta M; Kimura T; Nakamori M; Matsumura T; Fujimura H; Jinnai K; Takahashi MP; Mochizuki H; Yoshikawa H
Neuroreport; 2018 Feb; 29(3):235-240. PubMed ID: 29381654
[TBL] [Abstract][Full Text] [Related]
12. Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.
Carpentier C; Ghanem D; Fernandez-Gomez FJ; Jumeau F; Philippe JV; Freyermuth F; Labudeck A; Eddarkaoui S; Dhaenens CM; Holt I; Behm-Ansmant I; Marmier-Gourrier N; Branlant C; Charlet-Berguerand N; Marie J; Schraen-Maschke S; Buée L; Sergeant N; Caillet-Boudin ML
Biochim Biophys Acta; 2014 Apr; 1842(4):654-64. PubMed ID: 24440524
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
[TBL] [Abstract][Full Text] [Related]
14. Synaptic protein dysregulation in myotonic dystrophy type 1: Disease neuropathogenesis beyond missplicing.
Hernández-Hernández O; Sicot G; Dinca DM; Huguet A; Nicole A; Buée L; Munnich A; Sergeant N; Gourdon G; Gomes-Pereira M
Rare Dis; 2013; 1():e25553. PubMed ID: 25003003
[TBL] [Abstract][Full Text] [Related]
15. Aberrantly spliced alpha-dystrobrevin alters alpha-syntrophin binding in myotonic dystrophy type 1.
Nakamori M; Kimura T; Kubota T; Matsumura T; Sumi H; Fujimura H; Takahashi MP; Sakoda S
Neurology; 2008 Feb; 70(9):677-85. PubMed ID: 18299519
[TBL] [Abstract][Full Text] [Related]
16. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
Cho DH; Tapscott SJ
Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol enhances splicing of insulin receptor exon 11 in myotonic dystrophy type 1 fibroblasts.
Takarada T; Nishida A; Takeuchi A; Lee T; Takeshima Y; Matsuo M
Brain Dev; 2015 Aug; 37(7):661-8. PubMed ID: 25476247
[TBL] [Abstract][Full Text] [Related]
18. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing.
Charlet-B N; Savkur RS; Singh G; Philips AV; Grice EA; Cooper TA
Mol Cell; 2002 Jul; 10(1):45-53. PubMed ID: 12150906
[TBL] [Abstract][Full Text] [Related]
19. [Misregulation of alternative splicing and microRNA processing in DM1 pathogenesis].
Furling D
Rinsho Shinkeigaku; 2012; 52(11):1018-22. PubMed ID: 23196502
[TBL] [Abstract][Full Text] [Related]
20. ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I.
Leroy O; Dhaenens CM; Schraen-Maschke S; Belarbi K; Delacourte A; Andreadis A; Sablonnière B; Buée L; Sergeant N; Caillet-Boudin ML
J Neurosci Res; 2006 Sep; 84(4):852-9. PubMed ID: 16862542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
